Latest Medicinal Cannabis News

Page 5 of 8
Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.
Ada Torres
Ada Torres
29 Aug 2025
Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.
Ada Torres
Ada Torres
29 Aug 2025
ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.
Ada Torres
Ada Torres
29 Aug 2025
Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.
Victor Sage
Victor Sage
29 Aug 2025
ECS Botanics Holdings Ltd reported a $5.7 million net loss for FY2025 amid a strategic pivot from B2B to B2C sales and significant impairments. The company aims for a turnaround in FY2026 driven by new product launches and expanded production capacity.
Ada Torres
Ada Torres
29 Aug 2025
Vitura Health Limited has announced its third fully franked dividend of 0.2 cents per share following a profitable FY2025, reinforcing its unique position in the medicinal cannabis sector. Shareholders are invited to participate in a discounted Dividend Reinvestment Plan.
Ada Torres
Ada Torres
25 Aug 2025
Vitura Health reported modest revenue growth but a robust 23.5% increase in EBITDA for FY2025, fueled by key acquisitions and expanding telehealth services. Despite margin pressures in medicinal cannabis, the company’s strategic reset under new leadership sets the stage for further growth.
Ada Torres
Ada Torres
25 Aug 2025
Vitura Health reported a modest revenue increase to $124 million for FY2025, while net profit dipped 5.35% due to margin pressures and investment in new platforms. The company declared a fully franked dividend and highlighted growth in telehealth and medical services.
Ada Torres
Ada Torres
25 Aug 2025
Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.
Ada Torres
Ada Torres
31 July 2025
Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.
Ada Torres
Ada Torres
29 July 2025
ECS Botanics reports a 20% quarterly surge in direct-to-consumer sales and a record medicinal cannabis harvest, supported by an expanded loan facility to fuel further growth.
Ada Torres
Ada Torres
28 July 2025
Bod Science Limited reports a dramatic reduction in half-year losses alongside revenue growth driven by a strategic shift to THC products. The company remains under a Deed of Company Arrangement with key corporate actions pending shareholder approval.
Ada Torres
Ada Torres
25 July 2025